Skip to main content
main-content

16.03.2016 | Original Paper | Ausgabe 4/2016

Cellular Oncology 4/2016

Prognostic implications of securin expression and sub-cellular localization in human breast cancer

Zeitschrift:
Cellular Oncology > Ausgabe 4/2016
Autoren:
N. Gurvits, H. Repo, E. Löyttyniemi, M. Nykänen, J. Anttinen, T. Kuopio, K. Talvinen, P. Kronqvist

Abstract

Purpose

Securin belongs to a class of cell cycle regulators that prevent metaphase-to-anaphase transition until sister chromatid separation is complete. Evidence is accumulating that securin has a prognostic impact on a variety of malignancies but, thus far, the role and regulation of securin expression and its sub-cellular localization have not been systematically addressed in breast cancer.

Methods

In total 470 breast cancer specimens with follow-up data for up to 22 years were included. Immunohistochemical staining and immunofluorescence double-staining were performed for securin and its regulating proteins PTTG1IP, CDC20 and BUBR1. Prognostic associations were evaluated between the expression patterns of these proteins and established prognosticators of invasive breast cancer and patient survival.

Results

We found that a high fraction of securin expressing cancer cells predicted an unfavorable clinical outcome of the breast cancer patients (p < 0.001). Also in multivariate analyses, the fraction of securin expressing cancer cells served as an independent prognosticator of a poor survival (p < 0.0001). We also found that the sub-cellular localization of securin exhibited prognostic power, since cytoplasmic securin expression in the cancer cells appeared to be associated with aggressive breast cancer subtypes and high breast cancer-associated mortality rates (p = 0.003). Through immunofluorescence double-staining, we found that PTTG1IP, CDC20 and BUBR1 exhibited distinct patterns of co-expression with securin, suggesting a regulatory role in the metaphase-to-anaphase transition in human breast cancer cells. We also noted that a subgroup of triple-negative breast carcinomas exhibited deviant expression patterns for the proteins studied.

Conclusions

Our data indicate that securin expression may serve as a strong and independent prognosticator of breast cancer outcome and that a cytoplasmic localization of the protein may provide additional prognostic information, particularly in the biologically and clinically challenging subgroup of triple-negative breast carcinomas. The sub-cellular localization of securin appears to reflect the expression of PTTG1IP, CDC20 and BUBR1, which may participate in the regulation of securin activity and, ultimately, in the survival of breast cancer patients.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2016

Cellular Oncology 4/2016Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Pathologie

26.06.2018 | Prostatakarzinom | CME | Ausgabe 4/2018

CME: Neuroendokrines Prostatakarzinom

19.06.2018 | Schwerpunkt: Pathologie und Forschungsbiobanken | Ausgabe 4/2018

Der Aufbau und Betrieb einer Zentralen Biomaterialbank

Die ZeBanC der Charité Berlin

06.06.2018 | Schwerpunkt: Pathologie und Forschungsbiobanken | Ausgabe 4/2018

Biobanking und die Weiterentwicklung der Präzisionsmedizin

23.05.2018 | Schwerpunkt: Pathologie und Forschungsbiobanken | Ausgabe 4/2018

Alle unter einem Dach

Erfolge und Herausforderungen auf dem Weg zu einer zentralisierten Biobank am Beispiel der BMBH